Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer
Identification of effective biomarkers is crucial for monitoring the treatment and remission of colorectal cancer (CRC) and improving survival. It is particularly important to diagnose CRC before the tumor metastasizes (stage I–II disease) where possible, to provide the greatest opportunity for pati...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00921/full |
id |
doaj-0da57e7e88ff4746827e3c4e191f4a06 |
---|---|
record_format |
Article |
spelling |
doaj-0da57e7e88ff4746827e3c4e191f4a062020-11-25T02:32:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-10-01910.3389/fonc.2019.00921456014Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal CancerLonghai Li0Lihua Zhang1Yu Tian2Ting Zhang3Guangliang Duan4Yankui Liu5Yuan Yin6Dong Hua7Xiaowei Qi8Yong Mao9Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, ChinaSchool of Pharmacy, Jiangnan University, Wuxi, ChinaDepartment of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, ChinaWuxi Oncology Institute, Affiliated Hospital of Jiangnan University, Wuxi, ChinaDepartment of Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, ChinaDepartment of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, ChinaWuxi Oncology Institute, Affiliated Hospital of Jiangnan University, Wuxi, ChinaDepartment of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, ChinaDepartment of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, ChinaDepartment of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, ChinaIdentification of effective biomarkers is crucial for monitoring the treatment and remission of colorectal cancer (CRC) and improving survival. It is particularly important to diagnose CRC before the tumor metastasizes (stage I–II disease) where possible, to provide the greatest opportunity for patient recovery. Here, we evaluated the clinical value of serum chemokine (C-X-C) ligand 7 (CXCL7) concentration as a biomarker for CRC diagnosis. An enzyme-linked immunosorbent assay was used to measure CXCL7 concentration in 560 serum samples from patients with CRC and controls. Logistic regression and receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic efficacy and build mathematical diagnostic models. The concentration of CXCL7 in the CRC group was significantly higher than that in the control group (P < 0.001), with an area under the ROC curve (AUC) value of 0.862 [95% confidence interval (CI): 0.831–0.890]. Further, the AUC of a regression model including the markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 125 (CA125), along with CXCL7, was 0.933 (95% CI: 0.909–0.952). For stage I–II tumors, CXCL7 had the highest AUC (0.823, 95% CI: 0.783–0.858) among the four individual biomarkers. The AUC value for combination model analysis of samples from patients with stage I–II tumors was 0.904 (95% CI: 0.872–0.930), with a sensitivity of 82.76% and a specificity of 87.14%, and an optimal cut-off value of 2.66. AUC values for application of the regression model in subgroup analysis were 0.947 (0.917–0.968) and 0.919 (0.874–0.951) for males and females, respectively. These results suggest that CXCL7 has potential as a serum diagnostic biomarker for detection of CRC. Importantly, the combination of CXCL7, CEA, CA125, and CA19-9 may facilitate diagnosis of CRC with relatively high sensitivity and specificity.Clinical Trial Registration Number: LS2017001.https://www.frontiersin.org/article/10.3389/fonc.2019.00921/fullcancer biomarkercolorectal cancerCXCL7diagnosisserum |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Longhai Li Lihua Zhang Yu Tian Ting Zhang Guangliang Duan Yankui Liu Yuan Yin Dong Hua Xiaowei Qi Yong Mao |
spellingShingle |
Longhai Li Lihua Zhang Yu Tian Ting Zhang Guangliang Duan Yankui Liu Yuan Yin Dong Hua Xiaowei Qi Yong Mao Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer Frontiers in Oncology cancer biomarker colorectal cancer CXCL7 diagnosis serum |
author_facet |
Longhai Li Lihua Zhang Yu Tian Ting Zhang Guangliang Duan Yankui Liu Yuan Yin Dong Hua Xiaowei Qi Yong Mao |
author_sort |
Longhai Li |
title |
Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer |
title_short |
Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer |
title_full |
Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer |
title_fullStr |
Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer |
title_full_unstemmed |
Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer |
title_sort |
serum chemokine cxcl7 as a diagnostic biomarker for colorectal cancer |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2019-10-01 |
description |
Identification of effective biomarkers is crucial for monitoring the treatment and remission of colorectal cancer (CRC) and improving survival. It is particularly important to diagnose CRC before the tumor metastasizes (stage I–II disease) where possible, to provide the greatest opportunity for patient recovery. Here, we evaluated the clinical value of serum chemokine (C-X-C) ligand 7 (CXCL7) concentration as a biomarker for CRC diagnosis. An enzyme-linked immunosorbent assay was used to measure CXCL7 concentration in 560 serum samples from patients with CRC and controls. Logistic regression and receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic efficacy and build mathematical diagnostic models. The concentration of CXCL7 in the CRC group was significantly higher than that in the control group (P < 0.001), with an area under the ROC curve (AUC) value of 0.862 [95% confidence interval (CI): 0.831–0.890]. Further, the AUC of a regression model including the markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 125 (CA125), along with CXCL7, was 0.933 (95% CI: 0.909–0.952). For stage I–II tumors, CXCL7 had the highest AUC (0.823, 95% CI: 0.783–0.858) among the four individual biomarkers. The AUC value for combination model analysis of samples from patients with stage I–II tumors was 0.904 (95% CI: 0.872–0.930), with a sensitivity of 82.76% and a specificity of 87.14%, and an optimal cut-off value of 2.66. AUC values for application of the regression model in subgroup analysis were 0.947 (0.917–0.968) and 0.919 (0.874–0.951) for males and females, respectively. These results suggest that CXCL7 has potential as a serum diagnostic biomarker for detection of CRC. Importantly, the combination of CXCL7, CEA, CA125, and CA19-9 may facilitate diagnosis of CRC with relatively high sensitivity and specificity.Clinical Trial Registration Number: LS2017001. |
topic |
cancer biomarker colorectal cancer CXCL7 diagnosis serum |
url |
https://www.frontiersin.org/article/10.3389/fonc.2019.00921/full |
work_keys_str_mv |
AT longhaili serumchemokinecxcl7asadiagnosticbiomarkerforcolorectalcancer AT lihuazhang serumchemokinecxcl7asadiagnosticbiomarkerforcolorectalcancer AT yutian serumchemokinecxcl7asadiagnosticbiomarkerforcolorectalcancer AT tingzhang serumchemokinecxcl7asadiagnosticbiomarkerforcolorectalcancer AT guangliangduan serumchemokinecxcl7asadiagnosticbiomarkerforcolorectalcancer AT yankuiliu serumchemokinecxcl7asadiagnosticbiomarkerforcolorectalcancer AT yuanyin serumchemokinecxcl7asadiagnosticbiomarkerforcolorectalcancer AT donghua serumchemokinecxcl7asadiagnosticbiomarkerforcolorectalcancer AT xiaoweiqi serumchemokinecxcl7asadiagnosticbiomarkerforcolorectalcancer AT yongmao serumchemokinecxcl7asadiagnosticbiomarkerforcolorectalcancer |
_version_ |
1724819124778958848 |